Methotrexate Gry

Methotrexate Disodium, the active ingredient in Methotrexate Gry, is an antimetabolite presented as an injectable solution for intravenous use. It inhibits dihydrofolate reductase, reducing DNA synthesis and cell replication, which makes it effective in conditions such as rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and osteosarcoma.

GNH USA supplies Methotrexate Gry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate Gry is used in several disease categories where inhibition of cell proliferation is therapeutic.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell turnover, improving plaque severity. - Acute lymphoblastic leukemia: induces remission by targeting malignant lymphoblasts. - Osteosarcoma: impedes tumor growth and metastasis in bone cancer.

Methotrexate Gry may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after infusion. - Fatigue: persistent tiredness not relieved by rest. - Elevated liver enzymes: mild hepatic transaminase rise detectable on labs. - Mouth sores: ulceration of oral mucosa. - Low blood counts: mild neutropenia or anemia.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Severe hepatotoxicity: significant liver injury requiring monitoring. - Renal impairment: acute kidney injury due to precipitation of drug crystals. - Myelosuppression: profound pancytopenia increasing infection risk. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Methotrexate Gry requires careful monitoring and patient selection to minimize risks.

- Renal function: assess baseline and monitor renal parameters regularly. - Hepatic health: perform liver function tests before and during therapy. - Hematologic status: conduct complete blood counts to detect myelosuppression. - Pulmonary assessment: evaluate for pre‑existing lung disease and monitor respiratory symptoms. - Concomitant medications: avoid drugs that impair renal clearance or increase toxicity. - Pregnancy and lactation: contraindicated; ensure effective contraception. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate Gry can interact with several agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity by reducing renal clearance. - Proton pump inhibitors: may elevate serum methotrexate levels. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate myelosuppression.

Moderate Interactions (Monitor Closely): - Penicillins: may modestly increase methotrexate concentrations. - Sulfonamides: can enhance hematologic toxicity. - Vitamin supplements containing folic acid: may reduce therapeutic effect if not appropriately timed.